Biocartis Group NV: Disclosure of a transparency notification
PRESS RELEASE: REGULATED INFORMATION
12 January 2018, 07:00 CET
Disclosure of a transparency notification
(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)
Mechelen, Belgium, 12 January 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 11 January 2018 (the 'Notification'), indicating that the shareholding of Hitachi Chemical Co., Ltd. has decreased below the 3% notification threshold. It concerns a passive downward crossing of the lowest notification threshold.
The Notification contains the following information:
· Reason for the Notification: Passive crossing of a threshold. Downward crossing of the lowest threshold.
· Notification by: A parent undertaking or a controlling person.
· Persons subject to the notification requirement: Hitachi Chemical Co., Ltd., GRANTOKYO SOUTH TOWER, 1-9-2, Marunouchi, Chiyoda-ku, Tokyo, 100-6606, Japan; Hitachi, Ltd., 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, 100-8280 Japan.
· Transaction date: 28 November 2017.
· Threshold that is crossed: 3%.
· Denominator: 51,069,272.
· Details of the Notification: Hitachi Chemical Co., Ltd. holds 1,417,346 voting rights (representing 2.78% of the voting rights in Biocartis on the basis of the denominator set out above).
· Chain of controlled undertakings through which the holding is effectively being held: 51.2% shares of Hitachi Chemical Co., Ltd. is directly held by Hitachi, Ltd., which is a parent company of Hitachi Chemical Co., Ltd. Hitachi, Ltd. is not a csontrolled entity.
The Notification is available here on the website of the Company.
Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
----- END ----
Manager Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729 | mobile +32 471 53 60 64
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers twelve oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla(TM) trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.